TY - JOUR
T1 - Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma
T2 - Treatment outcome and prognostic factor analysis
AU - Shi, Youwu
AU - Zhou, Shengyu
AU - He, Xiaohui
AU - Han, Xiaohong
AU - Wu, Shikai
AU - Pan, Feng
AU - Liu, Peng
AU - Liu, Yinyu
AU - Lei, Yingheng
AU - Zhang, Hongzhi
AU - Yang, Jianliang
AU - Qin, Yan
AU - Zhang, Changgong
AU - Yang, Sheng
AU - Zhao, Liya
AU - Luo, Kehuan
AU - Wu, Guanqing
AU - Sun, Yan
AU - Shi, Yuankai
N1 - Publisher Copyright:
© Chinese Journal of Cancer Research. All rights reserved.
PY - 2015
Y1 - 2015
N2 - Objective: The study evaluated the effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of lymphoblastic lymphoma (LL). Methods: We retrospectively analyzed the data from 41 patients with chemotherapy-sensitive LL who underwent hematopoietic stem cell transplantation (HSCT) from December 1989 to December 2009 in a single institution. Results: HSCT was conducted as first-line consolidation therapy and salvage therapy in 36 and 5 patients, respectively. The median follow-up was 97.1 months (range, 24.6-173.1 months). The 5-year overall survival (OS) and event-free survival (EFS) rate were 64% and 47% for the initially treated patients, respectively, and were both 20% for the relapsed ones. Bone marrow (BM) involvement and chemotherapy cycles prior to transplantation were identified as significant prognostic factors for EFS in multivariate analysis. Conclusions: These results confirm that AHSCT is a reasonable option for chemotherapy-sensitive LL patients in first complete remission (CR1).
AB - Objective: The study evaluated the effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of lymphoblastic lymphoma (LL). Methods: We retrospectively analyzed the data from 41 patients with chemotherapy-sensitive LL who underwent hematopoietic stem cell transplantation (HSCT) from December 1989 to December 2009 in a single institution. Results: HSCT was conducted as first-line consolidation therapy and salvage therapy in 36 and 5 patients, respectively. The median follow-up was 97.1 months (range, 24.6-173.1 months). The 5-year overall survival (OS) and event-free survival (EFS) rate were 64% and 47% for the initially treated patients, respectively, and were both 20% for the relapsed ones. Bone marrow (BM) involvement and chemotherapy cycles prior to transplantation were identified as significant prognostic factors for EFS in multivariate analysis. Conclusions: These results confirm that AHSCT is a reasonable option for chemotherapy-sensitive LL patients in first complete remission (CR1).
KW - Allogeneic
KW - Autologous
KW - Hematopoietic stem cell transplantation (HSCT)
KW - High-dose therapy (HDT)
KW - Lymphoblastic lymphoma (LL)
UR - http://www.scopus.com/inward/record.url?scp=84940185405&partnerID=8YFLogxK
U2 - 10.3978/j.issn.1000-9604.2015.02.04
DO - 10.3978/j.issn.1000-9604.2015.02.04
M3 - Article
AN - SCOPUS:84940185405
SN - 1000-9604
VL - 27
SP - 66
EP - 73
JO - Chinese Journal of Cancer Research
JF - Chinese Journal of Cancer Research
IS - 1
ER -